T1	Participants 91 113	French clinical trials
T2	Participants 336 511	patients with hepatocellular carcinoma (HCC) and to explore how to improve prognostic classification among French patients with HCC whose main etiology is alcoholic cirrhosis.
T3	Participants 667 687	416 and 122 patients
